Ontology highlight
ABSTRACT:
SUBMITTER: Yamazaki T
PROVIDER: S-EPMC5297975 | biostudies-literature | 2017 Jan
REPOSITORIES: biostudies-literature
Yamazaki Takao T Desai Amit A Goldwater Ronald R Han David D Howieson Corrie C Akhtar Shahzad S Kowalski Donna D Lademacher Christopher C Pearlman Helene H Rammelsberg Diane D Townsend Robert R
Clinical pharmacology in drug development 20160715 1
This report describes phase 1 clinical trials performed to assess interactions of oral isavuconazole at the clinically targeted dose (200 mg, administered as isavuconazonium sulfate 372 mg, 3 times a day for 2 days; 200 mg once daily [QD] thereafter) with single oral doses of the cytochrome P450 (CYP) substrates: bupropion hydrochloride (CYP2B6; 100 mg; n = 24), repaglinide (CYP2C8/CYP3A4; 0.5 mg; n = 24), caffeine (CYP1A2; 200 mg; n = 24), dextromethorphan hydrobromide (CYP2D6/CYP3A4; 30 mg; n ...[more]